Discover the causes behind fatty liver disease, a condition affecting 25% of adults worldwide, and learn simple lifestyle ...

The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.

Maintaining optimal digestive health is crucial for overall well-being in today's fast-paced world. Many individuals struggle ...

Researchers have developed an advanced model that facilitates the study of drug metabolism during pregnancy by ...

A study published in Nature Aging has revealed a promising new drug candidate that may help combat metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver condition that ...

Metabolic Associated Fatty Liver Disease (MAFLD) has emerged as a global public health concern due to its increasing ...

"It is a long way from insights in mouse experiments to bringing a drug to the market – but this is obviously the potential ...

Tv Therapeutics (VTVT) announced that the United States Food and Drug Administration has lifted the clinical hold on the cadisegliatin ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes. CATT1 Phase 3 trial expected to ...

Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...

liver failure or cancer. Currently, there is no approved drug that can stop the disease from getting worse, making it a major health concern. A recent study published on January 31, 2024 ...

More than 100 million Americans struggle with obesity and related metabolic disorders, a staggering number with widespread consequences. "We were really excited about this work," says S. Thai ...